SCHEMBL3124156

SCHEMBL3124156

CCOC(=O)C12CN(Cc3ccccc3)CC1c1cccc3c1N(CCCO3)C2=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
GAA P10253 2/20 0.42
POLB P06746 2/20 0.41
SIGMAR1 Q99720 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
MEN1 O00255 5/20 0.39
KMT2A Q03164 5/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 2/20 0.39
MAPT P10636 1/20 0.39
PKM P14618 1/20 0.39
KDM4E B2RXH2 2/20 0.39
LMNA P02545 3/20 0.38
MAPK1 P28482 2/20 0.38
OPRM1 P35372 1/20 0.38
OPRD1 P41143 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141592 0.86 KDM4E (0.44) ALDH1A1GAAPOLBSIGMAR1L3MBTL1
SCHEMBL3137972 0.84 L3MBTL1 (0.43) ALDH1A1GAAPOLBSIGMAR1L3MBTL1
SCHEMBL13627296 0.70 L3MBTL1 (0.41) ALDH1A1GAAPOLBSIGMAR1L3MBTL1
SCHEMBL4481434 0.70 L3MBTL1 (0.41) ALDH1A1GAAPOLBSIGMAR1L3MBTL1
SCHEMBL4481436 0.70 L3MBTL1 (0.41) ALDH1A1GAAPOLBSIGMAR1L3MBTL1
SCHEMBL3136449 0.70 DRD2 (0.48) SIGMAR1CYP2D6
SCHEMBL3136453 0.70 DRD2 (0.48) SIGMAR1CYP2D6
SCHEMBL7565511 0.65 SIGMAR1 (0.41) ALDH1A1SIGMAR1CYP2D6
SCHEMBL3135456 0.65 OPRM1 (0.36) ALDH1A1GAAPOLBSMN1; SMN2MEN1
SCHEMBL3137980 0.65 HPGD (0.35) ALDH1A1MEN1KMT2ALMNAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399445-B9 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2010-07-21 EP disclosed
EP-1399445-B1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL MYERS SQUIBB CO (US) 2009-08-05 EP disclosed
US-6777406-B2 SUCH AS PYRIDO(3,2,1-IJ)PYRROLO(3,4-C)QUINOLIN-8-ONE DERI-VATIVES; CENTRAL NERVOUS SYSTEM DISORDERS; GASTROINTESTINAL DISORDERS BRISTOL-MYERS SQUIBB PHARMA COMPANY 2004-08-17 US disclosed
US-20040092502-A1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS BRISTOL-MYERS SQUIBB COMPANY, (FORMERLY D/B/A DUPONT PHARMACEUTICALS COMPANY) 2004-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092502-A1 SUBSTITUTED PYRROLOQUINOLINES AND PYRIDOQUINOLINES AS SEROTONIN AGONISTS AND ANTAGONISTS HTR1B, HTR2B, HTR1A ALDH1A1 2874/4885GAA 3057/4885POLB 1817/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.